German network against Neglected Tropical Diseases
However, the available methods, vaccines and medicines often do not reach the patients. In addition, there are still big gaps in prevention, control and treatment. Research and development into neglected tropical diseases must therefore urgently continue. The development of vaccines and medicines is indispensable in order to effectively fight multiple NTDs.
In industrialized countries, these diseases barely play a role owing to better hygiene and more moderate climate conditions. They are most widespread in poor countries located in the tropics and subtropics. Yet these areas often suffer from a lack of financial resources or medical infrastructure required to fight them. However, with suitable treatment programs and research plans, these diseases can be cured or the outbreak prevented from the start. Owing to joint efforts by civil society, politicians, science and business, an initial foundation has already been laid. The aim now is to jointly expand research, prevention and treatment activities as well to ensure that new medicines, vaccines and measures are developed. Existing medicines and vaccines must actually reach patients. This will help to eliminate many neglected tropical diseases in the foreseeable future.
World Health Assembly delegates approve WHO's new roadmap to tackle neglected tropical diseases for 2021-2030
Berlin/Geneva -12.11.2020. At the 73rd virtual session of the World Health Assembly, the delegates adopted the new roadmap to combat neglected tropical diseases for 2021-2030 by an overwhelming majority. Dagmar Reitenbach, delegate for Germany from the Federal Ministry of Health underlined in her statement the new possibilities in the coming decade to strengthen public health care through the new roadmap to combat NTDs.
Laboratory tests: drug against elephantiasis and river blindness stops coronavirus growth
Decatur, Georgia, April 7, 2020 - Mectizan Expert Committee stated: Australian researchers presented that the drug ivermectin shows activities against SARS-Cov-2. This is consistent to previous findings that ivermectin is also active against other viruses (such as HIV, dengue, influenza and Zika). Although the concentration of ivermectin needed to produce anti-viral effects in laboratory tissue culture is far beyond dosage levels approved. High dosis in animals have effected serious toxicity. These findings indicate that ivermectin will not be of clinical benefit to reduce viral loads in COVID-19 patients.
The Global Vector Hub presented on youtube
Berlin, April 4, 2020 - The Global Vector Hub is an open access, interactive resource presented on you tube. It has the capacity to transform vector research and vector control programmes, and to revolutionise the preparedness and ability to respond quickly and effectively to vector-borne disease outbreaks around the world.
More information on the youtube channel of the International Society for Neglected Tropical Diseases
COVID-19: WHO issues interim guidance for implementation of NTD programmes
Geneva, April 1, 2020 - The COVID-19 pandemic has prompted almost every country to implement unprecedented public health measures. WHO had issued an interim guidance for implementation of NTD programmes. A range of public health measures are being implemented that include hand hygiene, respiratory etiquette, and practicing physical distancing.
Uniting to Combat NTDs and COVID 19
London, March 23, 2020 - Uniting to Combat NTDs is concerned about the current Covid-19 pandemic and is monitoring the situation closely. They fully support the measures taken by the World Health Organization and partners to prevent and stop the spread of Covid-19. They indicate particularly the risk of the outbreak spreading to vulnerable, marginalized communities in the developing world. But have no doubt, that national Covid-19 responses will rely heavily on these established and trusted community systems, as was the case during the Ebola outbreak in West Africa in 2014-2016.
The German Federal Government answers to a small parliamentarian inquiry re the fight against neglected tropical diseases
Berlin, January 30, 2020 – The small parliamentarian inquiry was submitted by FDP (Liberal party) lead by MP Professor Dr. Andrew Ullmann. The opposition party wanted to know what the German government already has done and will do. Questions were addressed to the Federal Ministry of Education and Research (BMBF), the Federal Ministry for Economic Cooperation and Development (BMZ) and the Federal Ministry of Health (BMG).
Bernhard-Nocht-Institute establishes department for implementation research
Berlin/Hamburg, January 13, 2020 - The Bernhard-Nocht-Institute for Tropical Medicine (BNITM) is expanding its activities with a department dedicated to implementation research. At a ceremony, the invited guests emphasized the importance of the research branch, since it is not enough to just research and develop medicines and therapies. Rather, it is also about understanding how they are best brought to the sick and accepted by them. Therefore, implementation research should be organized in an interdisciplinary manner. In the future, social anthropologists, communication scientists, health economists will work together with colleagues from Africa at the BNITM. Prof. Dr. Jürgen May, head of implementation research and former spokesman for the German Network against Neglected Tropical Diseases, emphasized in the presence of Sabine Weiss, Parliamentary State Secretary at the Federal Ministry of Health, that one cannot rely on common sense alone. You have to be able to rely more on empirical results.
2020 – Else-Kröner-Fresenius medical development cooperation award for neglected tropical diseases
Berlin/Bad Homburg, January 2, 2020. The Else-Kröner-Fresenius Prize for Medical Development Cooperation 2020 is open to neglected tropical diseases. The award recognizes outstanding projects and employees of organizations that are committed to improving medical care in developing countries. The award is endowed with 100,000 Euros. Application deadline: February 15, 2020
Dengue vaccine factory opened
Singen, November 5, 2019. The Japanese pharmaceutical company Takeda has opened the first dengue vaccine factory in Germany. The company invested 130 million euros in the location Singen. Takeda is currently expecting approval by next year. The vaccine is still in approval-relevant phase 3 of the TIDES study (Tetravalent Immunization against Dengue Efficacy Study) and is being carried out in the dengue-endemic countries of Latin America and Asia. Dr. Dr. Carsten Köhler, member of the board of the DNTDs and director of the Competence Center Tropical Medicine Baden-Württemberg, Institute for Tropical Medicine of the University Clinic of the Eberhard-Karls-University Tübingen, points out that dengue is no longer just a travel illness and illness of neglected people, but already occurs locally in Europe.
Nobel Prize in Economics 2019 to poverty economist Esther Duflo
Stockholm, October 16, 2019. Esther Duflo, Michael Kremer and her husband Abhijit Banerjee received the Nobel Prize in Economics. They are the world's leading scientists in the field of evidence-based development cooperation. In 2007 they launched the Deworm the World Initiative. Since 2013, the initiative has been part of the non-profit organization Evidence Action, which is based in the USA and has offices in Kenya and India.